Navigation Links
Novel Vaccine Approach Offers Hope in Fight Against HIV
Date:5/17/2009

ed immunoadhesins) that were specifically designed to bind to SIV and block it from infecting cells. Once proven to work against SIV in the laboratory, DNA representing SIV-specific immunoadhesins was engineered into a carrier virus designed to deliver the DNA to monkeys. The researchers chose adeno-associated virus (AAV) as the carrier virus because it is a very effective way to insert DNA into the cells of a monkey or human.

In the second part of the study, the team injected AAV carriers into the muscles of monkeys, where the imported DNA produced immunoadhesins that entered the blood circulation. One month after administration of the AAV carriers, the immunized monkeys were injected with live, AIDS-causing SIV. The majority of the immunized monkeys were completely protected from SIV infection, and all were protected from AIDS. In contrast, a group of unimmunized monkeys were all infected by SIV, and two-thirds died of AIDS complications. High concentrations of the SIV-specific immunoadhesins remained in the blood for over a year.

Further studies need to be conducted if this technique is to become an actual preventive measure against HIV infection in people, Johnson said. "To ultimately succeed, more and better molecules that work against HIV, including human monoclonal antibodies, will be needed," he and his co-authors conclude. Finally, added Johnson, their approach may also have potential use in preventing other infectious diseases, such as malaria.

Grants from the National Institute of Allergic and Infectious Diseases of the National Institutes of Health supported this study. Johnson's collaborators, in addition to Clark, were Jianchao Zhang, of Nationwide Children's Hospital, Columbus, Ohio; Eloisa Yuste and Ronald C. Desrosiers of the New England Primate Research Center and Harvard Medical School; and Bruce C. Schnepp, Mary J. Connell, and Sean M. Greene, of Children's Hospital and the Univer
'/>"/>

SOURCE The Children's Hospital of Philadelphia
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials
2. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
3. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
4. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
7. Worldwide Sensation: "A"- Implant Novelty From Austria
8. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
9. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
10. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
11. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... announced that they have entered into an ... proprietary sd-rxRNA® technology for use in developing ... the potential to result in novel, more ... could be a significant step toward personalized ...
(Date:3/27/2015)... 27, 2015  Delcath Systems, Inc. (NASDAQ: ... company focused on oncology with an emphasis on ... announces the reporting of data from a single ... Injection with the Delcath Hepatic Delivery System (Melphalan/HDS) ... the Society of Surgical Oncology (SSO) Annual Meeting ...
(Date:3/26/2015)... 2015  The Burzynski Research Institute, Inc. (BRI) announced ... by the Department of Surgery at Kurume University ... have been published. The study, a randomized non-blinded ... as post-operative adjuvant therapy with and without Antineoplastons ... A total of 65 patients, ...
Breaking Medicine Technology:RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
... Reportlinker.com announces that a new ... its catalogue: Pharmaceutical ... Infrastructure Overview: Pharma innovates, diversifies and ... profits http://www.reportlinker.com/p0484917/Pharmaceutical-Key-Trends-2011----Pharmaceutical-Industry-Infrastructure-Overview-Pharma-innovates-diversifies-and-contains-cost-in-order-to-grow-profits.html ...
... Simcere Pharmaceutical Group (NYSE: SCR ), a ... marketing of branded generic and proprietary pharmaceuticals in China, ... results for the first quarter ended March 31, 2011 ... in the United States. Simcere,s management will host an ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Pharmaceutical Industry Infrastructure Overview: Pharma innovates, diversifies and contains cost in order to grow profits 4Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011 2
(Date:3/28/2015)... March 28, 2015 Genomic medicine experts ... mesothelioma, revealing, for the first time, key information for ... to read the newly posted story on the ... University of British Columbia, the British Columbia Cancer Agency, ... to reveal underlying molecular alterations and mutations that can ...
(Date:3/28/2015)... Lately the student-athlete experience has ... proposals around the NCAA. In a March episode of ... across a spectrum of universities and sports shed light ... special panel consists of athletes who have competed for ... track and field, baseball, and volleyball. They discuss the ...
(Date:3/28/2015)... Mirada, CA (PRWEB) March 28, 2015 ... ear, nose and throat disorders, are now ... is a common issue which is characterized by the ... Affecting 1 in 5 people, tinnitus is a prevalent ... disorder and while it is non-fatal, tinnitus can impede ...
(Date:3/28/2015)... March 28, 2015 Designers and Professionals ... overlay entitled Scratches 5K from Pixel Film Studios. , ... to any media inside Final Cut Pro X” Said ... saves time and is an effective tool for any ... Overlay Scratches 5K's intuitive grunge overlays. Simply drag title ...
(Date:3/28/2015)... NY (PRWEB) March 28, 2015 ... of dietary supplements announces the release of their ... was shown in two randomized, double-blind, placebo-controlled clinical ... and waist and hip size. MuffinStop™ is a ... indicus and Garcinia mangostana, fused together to create ...
Breaking Medicine News(10 mins):Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2
... WASHINGTON, D.C., October 5, 2011 The Merck ... than $4 million in funding to implement the ... Symptoms (CHAMPS) partnership in five non-profit, Federally Qualified ... (CHC) is designed to demonstrate how asthma management ...
... (October 4, 2011)In a new study led by Fox ... have found that Gleason scores determined by pathologists at ... of recurrence than Gleason scores from referring institutions. ... Meeting of the American Society for Radiation Oncology on ...
... new study from the University of Adelaide shows the parents of ... some form of cardiovascular disease. PCOS is a hormonal disorder ... one of the most common endocrine disorders in women and a ... with PCOS are more likely to have any form of cardiovascular ...
... HealthDay Reporter , TUESDAY, Oct. 4 (HealthDay News) -- Heart ... just as well if they are released the same day as ... research shows. "[Discharging patients the same day] wasn,t associated ... lead author of a study appearing in the Oct. 5 issue ...
... Oct. 5 (HealthDay News) -- Three hours of vigorous exercise ... 22 percent, a new study suggests. The Harvard School ... of that decreased risk was due to the beneficial effects ... (HDL) cholesterol. The findings were published Oct. 4 the ...
... (HealthDay News) -- ,A common structural variation in the brain ... details of past events and to distinguish real events from ... report. The study included 53 healthy adults who underwent ... a fold at the front of the brain called the ...
Cached Medicine News:Health News:Childhood asthma non-profit invests millions in health centers to help children better manage asthma 2Health News:Childhood asthma non-profit invests millions in health centers to help children better manage asthma 3Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 2Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 3Health News:Overnight Stay May Not Be Necessary for Stenting: Study 2Health News:Overnight Stay May Not Be Necessary for Stenting: Study 3Health News:MRI Study Unfolds Clues to Memory 2